Logo image of SRPT

SAREPTA THERAPEUTICS INC (SRPT) Stock Fundamental Analysis

NASDAQ:SRPT - Nasdaq - US8036071004 - Common Stock - Currency: USD

18.21  -1.02 (-5.3%)

After market: 18.32 +0.11 (+0.6%)

Fundamental Rating

3

Taking everything into account, SRPT scores 3 out of 10 in our fundamental rating. SRPT was compared to 558 industry peers in the Biotechnology industry. SRPT has a bad profitability rating. Also its financial health evaluation is rather negative. SRPT is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

SRPT had negative earnings in the past year.
In the past year SRPT has reported a negative cash flow from operations.
In the past 5 years SRPT reported 4 times negative net income.
In the past 5 years SRPT reported 4 times negative operating cash flow.
SRPT Yearly Net Income VS EBIT VS OCF VS FCFSRPT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M -400M -600M

1.2 Ratios

The Return On Assets of SRPT (-7.17%) is better than 86.02% of its industry peers.
SRPT has a Return On Equity of -21.74%. This is amongst the best in the industry. SRPT outperforms 84.23% of its industry peers.
Industry RankSector Rank
ROA -7.17%
ROE -21.74%
ROIC N/A
ROA(3y)-10.99%
ROA(5y)-12.97%
ROE(3y)-76.57%
ROE(5y)-69.51%
ROIC(3y)N/A
ROIC(5y)N/A
SRPT Yearly ROA, ROE, ROICSRPT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150

1.3 Margins

SRPT has a better Gross Margin (81.82%) than 86.02% of its industry peers.
In the last couple of years the Gross Margin of SRPT has remained more or less at the same level.
SRPT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 81.82%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.15%
GM growth 5Y-0.45%
SRPT Yearly Profit, Operating, Gross MarginsSRPT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K

More info and screens

3

2. Health

2.1 Basic Checks

SRPT does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SRPT has more shares outstanding
The number of shares outstanding for SRPT has been increased compared to 5 years ago.
The debt/assets ratio for SRPT has been reduced compared to a year ago.
SRPT Yearly Shares OutstandingSRPT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
SRPT Yearly Total Debt VS Total AssetsSRPT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

2.2 Solvency

Based on the Altman-Z score of -0.23, we must say that SRPT is in the distress zone and has some risk of bankruptcy.
With a decent Altman-Z score value of -0.23, SRPT is doing good in the industry, outperforming 61.83% of the companies in the same industry.
A Debt/Equity ratio of 1.00 indicates that SRPT is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 1.00, SRPT is doing worse than 76.34% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 1
Debt/FCF N/A
Altman-Z -0.23
ROIC/WACCN/A
WACC8.19%
SRPT Yearly LT Debt VS Equity VS FCFSRPT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B 1.5B

2.3 Liquidity

SRPT has a Current Ratio of 4.02. This indicates that SRPT is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of SRPT (4.02) is comparable to the rest of the industry.
A Quick Ratio of 2.46 indicates that SRPT has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 2.46, SRPT is doing worse than 68.10% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.02
Quick Ratio 2.46
SRPT Yearly Current Assets VS Current LiabilitesSRPT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

More info and screens

5

3. Growth

3.1 Past

The earnings per share for SRPT have decreased strongly by -2545.45% in the last year.
SRPT shows a strong growth in Revenue. In the last year, the Revenue has grown by 59.16%.
SRPT shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 37.94% yearly.
EPS 1Y (TTM)-2545.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1343.24%
Revenue 1Y (TTM)59.16%
Revenue growth 3Y39.42%
Revenue growth 5Y37.94%
Sales Q2Q%80.15%

3.2 Future

Based on estimates for the next years, SRPT will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.20% on average per year.
SRPT is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 3.03% yearly.
EPS Next Y-282.9%
EPS Next 2Y-16.02%
EPS Next 3Y-7.82%
EPS Next 5Y14.2%
Revenue Next Year19.49%
Revenue Next 2Y7.57%
Revenue Next 3Y6.75%
Revenue Next 5Y3.03%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
SRPT Yearly Revenue VS EstimatesSRPT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B 2B
SRPT Yearly EPS VS EstimatesSRPT Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 5 -5

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SRPT. In the last year negative earnings were reported.
SRPT is valuated reasonably with a Price/Forward Earnings ratio of 11.32.
96.06% of the companies in the same industry are more expensive than SRPT, based on the Price/Forward Earnings ratio.
SRPT is valuated cheaply when we compare the Price/Forward Earnings ratio to 35.33, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 11.32
SRPT Price Earnings VS Forward Price EarningsSRPT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SRPT Per share dataSRPT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 15 20

4.3 Compensation for Growth

SRPT's earnings are expected to decrease with -7.82% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-16.02%
EPS Next 3Y-7.82%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SRPT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SAREPTA THERAPEUTICS INC

NASDAQ:SRPT (7/15/2025, 8:23:51 PM)

After market: 18.32 +0.11 (+0.6%)

18.21

-1.02 (-5.3%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-06 2025-05-06/amc
Earnings (Next)07-30 2025-07-30/amc
Inst Owners96.57%
Inst Owner Change0%
Ins Owners4.4%
Ins Owner Change3.28%
Market Cap1.79B
Analysts76.36
Price Target58.82 (223.01%)
Short Float %15.63%
Short Ratio2.37
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-199.37%
Min EPS beat(2)-376.26%
Max EPS beat(2)-22.48%
EPS beat(4)2
Avg EPS beat(4)280.81%
Min EPS beat(4)-376.26%
Max EPS beat(4)1173.24%
EPS beat(8)6
Avg EPS beat(8)609.68%
EPS beat(12)7
Avg EPS beat(12)362.51%
EPS beat(16)9
Avg EPS beat(16)271.74%
Revenue beat(2)2
Avg Revenue beat(2)4.86%
Min Revenue beat(2)2.86%
Max Revenue beat(2)6.86%
Revenue beat(4)3
Avg Revenue beat(4)3.13%
Min Revenue beat(4)-9.09%
Max Revenue beat(4)11.9%
Revenue beat(8)6
Avg Revenue beat(8)4.15%
Revenue beat(12)9
Avg Revenue beat(12)3.16%
Revenue beat(16)11
Avg Revenue beat(16)2.72%
PT rev (1m)-38.21%
PT rev (3m)-65.86%
EPS NQ rev (1m)-17.41%
EPS NQ rev (3m)-71.23%
EPS NY rev (1m)-114.91%
EPS NY rev (3m)-147.16%
Revenue NQ rev (1m)-5.47%
Revenue NQ rev (3m)-29.78%
Revenue NY rev (1m)-12.71%
Revenue NY rev (3m)-27.98%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 11.32
P/S 0.8
P/FCF N/A
P/OCF N/A
P/B 1.57
P/tB 1.6
EV/EBITDA N/A
EPS(TTM)-2.69
EYN/A
EPS(NY)1.61
Fwd EY8.83%
FCF(TTM)-7.1
FCFYN/A
OCF(TTM)-5.57
OCFYN/A
SpS22.72
BVpS11.63
TBVpS11.36
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -7.17%
ROE -21.74%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 81.82%
FCFM N/A
ROA(3y)-10.99%
ROA(5y)-12.97%
ROE(3y)-76.57%
ROE(5y)-69.51%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.15%
GM growth 5Y-0.45%
F-Score2
Asset Turnover0.64
Health
Industry RankSector Rank
Debt/Equity 1
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 386.06%
Cap/Sales 6.73%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.02
Quick Ratio 2.46
Altman-Z -0.23
F-Score2
WACC8.19%
ROIC/WACCN/A
Cap/Depr(3y)221.92%
Cap/Depr(5y)219.29%
Cap/Sales(3y)6.11%
Cap/Sales(5y)8.05%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-2545.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1343.24%
EPS Next Y-282.9%
EPS Next 2Y-16.02%
EPS Next 3Y-7.82%
EPS Next 5Y14.2%
Revenue 1Y (TTM)59.16%
Revenue growth 3Y39.42%
Revenue growth 5Y37.94%
Sales Q2Q%80.15%
Revenue Next Year19.49%
Revenue Next 2Y7.57%
Revenue Next 3Y6.75%
Revenue Next 5Y3.03%
EBIT growth 1Y-23.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-136.36%
EBIT Next 3Y61.22%
EBIT Next 5Y26.72%
FCF growth 1Y-48.29%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-26.22%
OCF growth 3YN/A
OCF growth 5YN/A